To view this email as a web page, click here.

Industry updates
 
A new insurance world
Issues facing dermatologists not new, but opportunity exists to develop successful methods for gathering data.
Learn more.
 
ADVERTISEMENT
Advertisement
 
Brodalumab approved for psoriasis
Dr. Mark Lebwohl discusses FDA's approval of the newest anti-interleukin-17 receptor monoclonal antibody for treatment of adults with moderate-to-severe plaque psoriasis.
Drug proves itself with unprecedented PASI results but comes with a caution.
 
ADVERTISEMENT
 
We want to hear from you!
 
Join our Reader Reactor Panel
We are inviting members of our community to join our Reader Reactor Panel. This select group of individuals will help our brand keep the pulse on important issues facing you and your colleagues today.
Would you like to join us?
 
In case you missed it
 
The truth about isotretinoin
New challenges of melanoma
Starting a career in dermatology: 5 questions
 
DIGITAL EDITION
 
March features
Wound healing technologies, updated rosacea guidelines, nasal reconstruction and more are all inside this month's issue of Dermatology Times.
Catch up on today's trends
 
JOB OPPORTUNITIES
 
 
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.